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Abstract: Selection of inhibitor-resistant viral mutants is universal for viruses that display
quasi-species dynamics, and hepatitis C virus (HCV) is no exception. Here we review recent results
on drug resistance in HCV, with emphasis on resistance to the newly-developed, directly-acting
antiviral agents, as they are increasingly employed in the clinic. We put the experimental
observations in the context of quasi-species dynamics, in particular what the genetic and phenotypic
barriers to resistance mean in terms of exploration of sequence space while HCV replicates in
the liver of infected patients or in cell culture. Strategies to diminish the probability of viral
breakthrough during treatment are briefly outlined.
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1. Quasi-Species in the Interpretation of Virus Adaptability
Virologists define quasi-species as dynamic collections of viral genomes subjected to genetic
variation, competition, and selection, and which may act collectively as a unit of selection. This
definition arose as a consequence of the comparison of nucleotide sequences of individual genomes
present in RNA viral populations, and modification of mutant composition as a function of time,
both in cell culture and in vivo. Molecular or biological clones isolated from a viral population
deviated on average in one to several positions from many other genomes of the same population
and from the consensus sequence. The consensus or average sequence is the one that at each position
has the most abundant residue at that position in the aligned sequences. The imprint of classical
genetics, the way sequence data banks have been built, and the inertia of textbook contents, all
push to identify viral genomes with a defined nucleotide sequence. The reality is that due to low
fidelity replication, populations of RNA viruses—as well as several DNA viruses—consist of mutant
clouds rather than a defined sequence. A viral genome can only be defined statistically as a weighted
average of many different sequences at any given time, but the precise composition is indeterminate
and keeps changing as the virus replicates. Mutation is permanent, not occasional. An identical
consensus sequence in successive isolates of a viral lineage does not imply absence of mutations;
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it means that despite mutations occurring continuously, the variant genomes give rise to the same
average genomic sequence. The indeterminacy of the precise composition of a viral population at
any time is a resource that viruses exploit for adaptation. It translates into clinical uncertainties such
as how important it is to characterize minority genomes before implementing an antiviral protocol,
or how will a virus population respond to a given treatment, among other issues, some of which are
addressed in coming sections.
The term “unit of selection” included in the quasi-species definition deserves a comment. Viruses
subjected to error-prone replication are endowed with a double potential regarding their response to
a selective constraint: selection can act on an individual class of genomes (with the same nucleotide
sequence) or it may act on a set of genomes (with related nucleotide sequences). In the first case, a
single genome or genome class endowed with the adequate phenotype may be selected, irrespective
of other genomes around it. However, in their subsequent replication the selected genomes will
immediately generate an expanded mutant cloud. In the second case, it is an interconnected ensemble
of individuals which is selected at the same time. This dual potential of viral populations for
individual or group selection represents by itself a selective advantage over other types of organisms
whose populations do not interact internally to provide collective phenotypes as the target of selection
(as an overview of quasi-species as applied to viruses and other biological systems, see [1–4]).
Application of massive parallel sequencing technologies, also known as next generation
sequencing (NGS), has confirmed and extended the previous evidence based on molecular or
biological cloning and Sanger sequencing that viral populations are indeed very complex, with
many minority genomes present at least at 1% level, and most probably at lower levels ([5–11],
among other studies). Lower frequency levels are difficult to reach and characterize due to current
methodological limitations. Molecular or biological cloning, combined with Sanger sequencing,
despite reaching only about a 20% cut-off for mutation abundance, may still be considered a reference
methodology on which the basic quasi-species concepts were built (Sections 1 and 2). It can probe
long sequences, albeit with possible biases derived from using either molecular or biological cloning.
Molecular cloning may analyze non-infectious genomes while biological cloning may over-represent
the most infectious genomes [12–14]. The capacity of NGS to retrieve thousands of sequences
per sample is conditioned to identifying and pruning technical sequencing errors, an endeavor
which is facilitated by increasingly-effective bioinformatics procedures [15–18]. A combination of
tools to eliminate erroneous reads from NGS data is based on the following three general criteria:
(1) general single sequence quality control; (2) exclusion of rare chimeric sequences unlikely to belong
to true recombinant genomes; (3) setting a final abundance threshold considered above the noise
level [5,9,19–23] (additional features of NGS are summarized in Table 1). Sequencing coverage should
be especially taken into account since minority variants above 1% can only be considered if the
number of reads reaches a minimum (see point four of Table 1).
Table 1. Features of NGS which are relevant to the detection of drug resistance mutations.
Observations References
‚ Plasmids including point mutations might be used to setting up the detection limit
of low frequency resistant mutants within the NGS data treatment pipeline. [5,9,19,20]
‚ Each haplotype or point mutation (amplicon or shotgun strategy, respectively)
should be represented at comparable abundance in forward and reverse DNA
strands to be considered.
[5,9,19–23]
‚ There is a general consensus to filter out variants below 1%. However, the threshold
above which preexisting mutants may impact on treatment response in patients is
still under study.
[5–8,10]
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Table 1. Cont.
Observations References
‚ Based on DeLeeneer et al., the minimal number of reads to theoretically detect a
resistant mutant at 1% (observed not below 0.5%) should be 3250. Experimentally,
Thys et al., increased to 10,000 reads the minimal coverage to reliably detect minor
variants spiked at 1%.
[9,24]
‚ Reconstruction of full-length viral haplotypes is essential to study interactions
among mutations present in the same viral RNA molecule. Sequencing of long
reads based on single molecule, real-time technology will permit to define
such associations.
[25]
The application of NGS to viral quasi-species is forcing a redefinition of what is meant by
“conserved” sequences. The traditional invariance of consensus sequences cannot be equated with
absence of minority mutations (that have no effect on the consensus) at the relevant region. This is
not trivial since conservation in the classical sense (but not in a NGS resolution sense) is the point
of departure of designs that claim universal antiviral agents or universal vaccines as objective. The
number of publications that deal with the analysis of viral population complexity is increasing at a
considerable rate, and the reader is referred to a recent article and two books where the state of the
art is summarized, and where many previous studies are quoted [3,4,26].
The collections of genomes that compose viral populations are also termed mutant spectra,
mutant clouds or mutant swarms. The population structure denoted by these terms is not only based
on definitive experimental evidence, but has a conceptual origin in quasi-species theory developed by
M. Eigen and P. Schuster [27,28]. This theory had as its original purpose to explain self-organization
and adaptability of primitive genetic elements endowed with inheritable information that might
have provided the first replicating forms on Earth. Quasi-species theory is presently an active
field of theoretical research, and it has greatly influenced our understanding of basic principles of
living systems, including several aspects of virus biology [4]. The core mathematical equation of
quasi-species dynamics is not strictly unique. since it can be related to other equations that describe
evolutionary dynamics [29]. These relationships among alternative mathematical formulations have
one important qualification: the quasi-species equation incorporates mutation as an event inherent
to replication. This is not a trivial departure from the other formulations, at least as viruses are
concerned, since error-prone replication begs a prominent role of mutation. Additionally, again as an
inheritance of classic population genetics, a rooted concept was that mutation was a rare occurrence
among present day organisms, with little impact in their present evolution (see [3] for an overview).
The inherent association of mutation with replication included in quasi-species theory changed the
picture dramatically.
With regard to biological implications of quasi-species dynamics, they can be summarized by
saying that quasi-species may impact any viral feature whose performance may vary significantly as
a result of one or a few mutations. Very few individual mutations represented in a mutant spectrum
will confer genomes the capacity to respond to a specific selective constraint, but the myriads of
mutations gathered in a large ensemble will provide a reservoir capable of responding to multiple
constraints. Therefore, both mutant spectrum complexity and viral population size are determinants
of adaptability. Here we come to the connection between quasi-species and drug resistance, the focus
of the present article.
2. Molecular Basis of Quasi-Species Dynamics in Connection with Antiviral Drug Resistance
Mutant spectra originate from high mutation rates that, for RNA viruses, have been
calculated to be in the range of 10´3 to 10´5 mutations introduced per nucleotide copied, using
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biochemical and genetic procedures. The low fidelity of viral polymerases is due to two main
molecular mechanisms: (i) the inherently limited accuracy of nucleotide incorporation due to steric
requirements during template-directed nucleotide uptake at the polymerase active site; and (ii) the
absence of proofreading and post-replicative repair activities. Mechanism (i) is currently being
explored at an increasingly-accurate level of atomic resolution, thanks to combined structural and
biochemical approaches to the enzymology of viral replication (see as examples [30] and [31], and
references therein). Concerning mechanism (ii), the 31 to 51 exonuclease activities that can excise
incorrect nucleotides incorporated at the 31-end of the growing polynucleotide chain are absent
in most viral RNA polymerases, reverse transcriptases, and some cellular DNA polymerases. In
consequence, misincorporated nucleotides remain in the newly-synthesized viral nucleic acids. The
post-replicative repair activities operate during cellular DNA, but not viral RNA, replication, because
they recognize mismatches in double stranded DNA but not in double stranded RNA or DNA-RNA
hybrids. From the enzymology of DNA replication, a similar range of mutation rates is expected
for DNA viruses whose replication is catalyzed by polymerases devoid of proofreading-repair
activities, although mismatched nucleotides in DNA duplexes may be corrected [32]. It is not clear
if post-replicative repair activities are available in sufficient amounts to the replication factories
where replicating viral DNAs accumulate, and to what extent such activities diminish progeny
heterogeneity [3]. Thus, fundamental biochemical features of mutant generation fit the conceptual
postulates of quasi-species theory [4].
In a strict sense according to theory, the term viral quasi-species should refer to the ensemble
of genomes present in a single replicative unit; for example, at a replication complex inside an
infected cell where a direct dynamics of mutation, competition, and selection occurs. However, the
term quasi-species is used in a more relaxed manner to refer to viral genomes that may replicate
in different cells, tissues, or organs. This extension is justified since selective constraints and the
ensuing competition among viral variants can affect viruses that did not necessarily arise in the
same replicative unit. As an example, virus mutants in blood as a result of a systemic infection
may be differentially neutralized by antibodies or bind to antiviral agents to different extents,
thereby modulating which subpopulations will participate in subsequent replication rounds. These
selective processes can be best understood under the quasi-species framework (see [13] for medical
implications of viruses replicating as mutant swarms in infected individuals).
To better understand the connection between quasi-species and drug resistance, it is helpful to
visualize short-term evolution of viruses as movements in sequence space [13,33,34]. Sequence space
is a theoretical representation of all possible sequences available to a polymeric structure. In the
case of viral genomes, the total sequence space equals the length in nucleotides to the power of four,
since four are the types of monomeric units (nucleotides) that compose the genome. The theoretical
sequence space for any virus is an unimaginably large number. However, the portion of sequence
space compatible with virus replication, despite being large, is far more reduced, and it is in that
portion where events related to adaptability occur. An intuitively useful way to depict the behavior
of dynamic mutant clouds is to consider that they are continuously exploring neighbor positions
of sequence space, pushed by mutation and guided by fitness (differential rate of multiplication
of genome subsets). Each point (or set of points) in sequence space is associated with a relative
replicative performance in the face of environmental requirements [35].
The above description is also adequate to capture what “selection” means in viral quasi-species:
the replacement of some mutant swarm subpopulations by others, at a rate that depends on
the intensity of selection (the classic selection coefficient). Host cell tropism (sometimes with
consequences for host range modifications) is only one of many selective pressures that guide
movements of mutant clouds in sequence space. Molecular evidence suggests that fitness landscapes
(the variation of fitness value as a function of position in sequence space or the environment) are
extremely rugged for viruses [3]. The capacity to rapidly explore sequence space is a means to
survive in the face of such ruggedness. Furthermore, important features predicted by quasi-species
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theory—such as the existence of an error threshold for maintenance of genetic information, the
basis of the antiviral strategy known as lethal mutagenesis [13]—are maintained for rugged fitness
landscape [35].
One of the traits that can be easily selected is drug resistance. Next we address the origins of drug
resistance, first in general terms, and then for hepatitis C virus (HCV), at a time at which anti-HCV
therapies experience a drastic change through the introduction of many new specific antiviral agents.
Current developments with HCV offer an interesting counterpart to the extensive experience gained
with antiretroviral agents used to control HIV-1 infections, and the consequences of implementing
highly active antiretroviral therapies (HAART) since 1996.
3. Molecular and Population Aspects of drug Resistance
Drug- (or inhibitor-) resistant viral mutants are defined as those that can multiply more
efficiently than other components of the mutant spectrum in the presence of a drug (or inhibitor).
Their selection and maintenance in the viral population is influenced by host and viral factors. Among
the latter, six main parameters deserve a comment: (i) the average mutation rate during viral genome
replication; (ii) the replication rate that relates to the capacity of exploration of the sequence space;
(iii) the viral population size that measures the sequence space actually occupied by the virus; (iv) the
genetic barrier to drug resistance that depends on the number and types of mutations needed to attain
the resistance phenotype; (v) the phenotypic barrier to resistance that can be quantified as the fitness
cost inflicted upon the virus by the resistance mutations; and (vi) the prior evolutionary history of the
virus that may have fixed mutations that alter drug sensitivity or barriers to resistance. Most of these
parameters are connected, and their influence in the development of drug resistance is summarized
in the following paragraphs.
The occurrence of mutations that increase viral replication in the presence of a drug is a random
event and, as such, its frequency depends on how many genomes can mutate (the viral population
size), how fast they mutate (the mutation rate), and how fast they replicate (their net increase in
number as a function of time). These parameters are subjected to trade-offs and limitations. In
particular, the mutation rate must lie within some boundaries: too low or too high a rate may result
in suboptimal adaptability, as evidenced by the deleterious effect that changes in fidelity of template
copying often have on viruses [36]. The replication rate is limited by the molecular machinery of
initiation of nucleic acid synthesis and chain elongation; a few measurements suggest that a typical
viral RNA genome can be completed in 1 to 10 min (reviewed in [3]), which means efficient progeny
production and exploration of sequence space. A consequence of the effect of these parameters is
that suboptimal concentrations of inhibitors at the sites of viral replication will favor selection of
inhibitor-resistant mutants through maintenance of a replicative load in the presence of the selective
agent. Suboptimal inhibitor concentrations can be due to patients not adhering to the treatment
schedule, often resulting in treatment failure [37].
For any possible mutant (including drug-resistant mutants) that deviates from the dominant
sequence with optimal fitness (the master dominant sequence), the lower its fitness, the lower its
frequency in the mutant spectrum (ignoring possible effects of intra-quasi-species complementation
or interference). This is a basic principle of quasi-species dynamics, namely that the genomes in
a mutant spectrum are ranked according to fitness. If a resistance mutation inflicts a high fitness
cost, the relevant mutant will be found at low frequency, and it may not have a chance to become
dominant even in the presence of the drug, unless compensatory fitness-enhancing mutations are
introduced in the genomes. An unsolved issue is whether low frequency variants which lie at the limit
of detection of deep sequencing analyses are still able to replicate at low levels, thereby maintaining a
possibility of acquisition of compensatory mutations, or they remain as dead-end genomes unable
to evolve. Furthermore, mutant swarms are not mere aggregates of mutant genomes fueled by
mutational pressure. Internal interactions of complementation or interference may be established
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that may enhance or decrease, respectively, the proportion of individual variants, relative to what
might have been expected from their fitness measured in isolation (reviewed in [3,4]).
Both the short-term and long-term evolutionary histories are an important influence on drug
resistance. The occurrence of a bottleneck (drastic reduction of virus population size) may transiently
diminish population complexity and the probability that a specific mutation is found in the
population. Long term diversification of viruses in nature, which is defined as a fixation of variations
of the dominant nucleotide sequences, leads to increasing numbers of genotypes (GTs) and subtypes
that may differ in drug sensitivity or in the barriers to resistance (examples for HCV are given in
Section 4.2).
These introductory remarks of drug resistance viewed in the light of quasi-species dynamics
renders unsurprising that drug-escape mutants have been systematically described for pathogenic
viruses, ever since the first inhibitors became available [38,39]. The ultimate reason is error-prone
replication, which is shared by most pathogenic RNA (and several DNA) viruses (additional studies
on antiviral resistance have been reviewed in [13,40,41]).
4. Resistance to Anti-HCV Inhibitors and Treatment Failure
HCV infections may generate a chronic, progressive disease (chronic hepatitis C, or CHC) that,
in most cases, leads to cirrhosis, and constitutes an indication of liver transplantation. Persistent
suppression of viral replication can positively affect the course of the infection by impeding
disease progression. No vaccine to prevent HCV infection is available, and treatment relies on
pharmacological interventions that have seen a profound revolution during the last decade. Yet,
the problem of drug resistance and ensuing treatment failures continue being a major difficulty, as
examined next for the different historical and current treatment options.
4.1. Resistance to Interferon and Ribavirin
The first treatment for patients with CHC became available 30 years ago, and consisted
of interferon-alfa-2b (IFN-α-2b). Due to side effects (flu-like symptoms and neuropsychiatric
alterations), the adherence to this first treatment was limited, resulting in frequent virus
breakthrough. The IFN-only therapy failed to produce a sustained virological response (SVR) in
most patients, with SVR rates around 20% [42,43]. Resistance to IFN is a complex trait probably
because it requires multiple mutations throughout the HCV genome. According to model studies
in cell culture, IFN-α resistance is the result of a complex acquisition of non-synonymous adaptive
mutations scattered throughout the genome, accompanied with an increase of the shut-off of host cell
protein synthesis, and enhancement of phosphorylation of protein kinase R (PKR) and translation
initiation factor eIF2α [44]. The multiple cellular products involved in the IFN response may explain
why no clear picture of IFN-α resistance mutations in vivo is currently available.
The addition of the purine analogue ribavirin (RBV) to IFN therapy significantly improved
long-term virological response in treatment-naïve and treatment-experienced patients [45,46],
reaching SVR rates of around 40% [47]. The introduction of pegylated IFN-α (pegIFN-α2a or 2b),
used in combination with a body weight-adjusted RBV dose, provided improvements in both efficacy
and administration schedule [47]. This combination (abbreviated as pegIFN + RBV) became the
standard-of-care regimen for HCV therapy until 2011 [47,48]. Treatment adherence was still limited
due not only to IFN-α but also to reversible hemolytic anemia produced by RBV. Numerous clinical
trials revealed significantly different response rates that were dependent not only on drug dosage
and treatment duration, but on a number of host (allelic forms of some genes) and viral factors,
in particular the viral GT. SVR rates ranged from 45% to 93% depending on the viral GT, with the
following order of treatment efficacy: GT2 « GT3 « GT5 « GT6 > GT4 ě GT1 [49–53].
The molecular basis of the benefits due to inclusion of RBV in the treatment is not well
understood [54]. Several antiviral mechanisms of RBV have been described: (i) immunomodulation
and enhancement of the Th1 antiviral immune response; (ii) up-regulation of genes involved in IFN
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signaling; (iii) inhibition of viral RNA-dependent RNA polymerases; (iv) depletion of intracellular
GTP levels; (v) inhibition of mRNA cap formation; and (vi) lethal mutagenesis. Several lines of
evidence suggest that lethal mutagenesis is involved in the RBV-mediated viral inhibition during
anti-HCV therapy [55–59]. The mutagenic activity of RBV has been observed both in vivo [57] and
in cell culture [60], including a RBV-induced bias in the mutant spectrum which implies an excess
of G Ñ A and C Ñ U transitions. In general, selection of a resistance mutation against a classical
inhibitor is easier than for a mutagen [3]. The first identification of a RBV-resistance mutation (F415Y
in NS5B) in HCV was described in patients under RBV monotherapy [61]. Resistance was also
observed in HCV replicon-containing cell lines, and it occurred through changes in the cell line or
mutations in NS5A (G404S and E442G). Reduced drug uptake has been proposed as a mechanism
for RBV resistance [62,63]. Additionally, serial passage of a GT2a replicon in the presence of RBV
resulted in reduced sensitivity to the drug that was associated with NS5B mutation Y33H, apparently
due to a reduction in replicative fitness [64]. Passage of infectious J6/JFH1 chimeric HCV in the
presence of RBV resulted in a resistant virus, although the mutations responsible for resistance were
not identified [65].
4.2. Resistance To Directly Acting Antiviral Agents and Host-Targeting Agents
Since 2011, a new generation of anti-HCV agents, termed Directly-Acting Antivirals (or DAAs)
entered the picture of anti-HCV therapy, resulting in great improvement of SVR rates. These new
inhibitors target the NS3/4A protease, the non-structural protein NS5A or the viral polymerase
NS5B [66,67]. With the introduction of the first-generation HCV NS3/4A protease inhibitors (PI),
telaprevir (TPV), and boceprevir (BOC), which are given in combination with pegIFN + RBV, the SVR
rates have significantly increased by more than 30%. However, in 20% to 40% of patients, treatment
fails and viral load reappears either during therapy (“breakthrough”), or upon treatment interruption
(“relapse”). More recently, the approval of new DAAs, such as simeprevir (directed to NS3/4A),
daclatasvir (DCV)(directed to NS5A), and sofosbuvir (SOF)(directed to NS5B), as well as oral IFN-free
combinations such as ledipasvir/SOF (Harvoni) (directed to NS5A and NS5B, respectively) and triple
therapy paritaprevir/ritonavir + ombitasvir + dasabuvir (Viekirax and Exviera) (directed to NS3,
NS5A, and NS5B, respectively) have increased the SVR rate to more than 90% in clinical trials with
treatment-naïve and cirrhotic patients [67–72] (Figure 1).
Despite the potent, and highly-efficient, new treatment regimens, response data outside clinical
trials suggest that treatment for around 10% to 15% of patients will fail. A recent study in Denmark
showed that only 47% of the patients treated with a triple therapy including TPV or BOC in
combination with peg-IFN-α + RBV achieved SVR [73]. This percentage is much lower than that
attained in clinical trials. From the patients failing therapy, 71% included mutations that confer
resistance to PIs. Data from both in vitro analysis and from clinical trials have reliably identified
mutations that are associated with treatment failure (reviewed in [74,75]).
Many single amino acid changes are associated with reduced sensitivity to NS3/4A and NS5A
inhibitors being the barrier to resistance relatively low [76,77]. Resistance of HCV to nearly all
protease inhibitors is achieved by substitutions at key positions in NS3 (Arg 155, Ala 156, and
Asp 168) [77–79]. Substitutions at positions Met 28, Gln 30, Leu 31, Pro 32, and Tyr 93 in NS5A
are frequently selected by NS5A inhibitors [80–83]. In contrast, the barrier to resistance against NS5B
nucleoside analogs is relatively high. Nucleoside inhibitors of NS5B are analogs of the polymerase
substrates and bind to residues near the active site which is highly-conserved. As an example, SOF
is an approved pyrimidine-derived nucleoside analog NS5B inhibitor whose barrier to resistance
is relatively high. However, several substitutions in NS5B (L159F/L320F, T179A, S282T/G/C/R,
M289L, I293L, C316N, V321A, I434M) have been associated with SOF resistance, and compensatory
mutations (such as M343T and H479P) can contribute to fitness gain in the presence of the main
resistance mutation S282T [84–87].
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Substitution S282T has been selected in vivo in the course of different treatments that included
SOF [88–92]. Additional amino acid changes at position 282 (G/C/R) have been related with SOF
resistance using in silico models [6], and substitution S282G was also detected in several liver isolates
from one patient [93]. HCV offers a direct example of how rapid evolution of a virus in nature and
its diversification into GTs and subtypes [94] lead to differences in nucleotide composition that affect
the evolutionary pathways towards drug resistance. Several examples of differences in composition
of the triplets that encode amino acids in NS3 which participate in inhibitor resistance are given in
Figure 2. Such variations can affect the barrier to resistance because of the requirement of either one
or two transition or transversion mutations (indicated as ts and tv in Figure 2) to reach the required
amino acid. Therefore, virus diversification is, by itself, a source of disparate behavior in terms of
inhibitor sensitivities. HCV subtype is a key determinant on the efficacy of DAAs, with subtype
1a patients displaying lower response rates than those infected with subtype 1b [78,95]. A correct
subtyping is essential to decide which treatment is the most adequate for each patient and this is
now feasible due to NGS technologies [96]. It is still an open question whether resistance to DAAs
displaying high barrier to resistance will become a significant clinical issue for treatment failure or
not. Experience with other viral diseases suggests that the problem is likely to become relevant. It will
largely depend on the management of the new combinations to poorly responding patients—who
offer environments that are prone to select for escape mutants—, on the initial fitness capacity of
exploration of sequence space for further fitness increases (compare with Section 2), and also on the
frequency of transmission of the newly generated mutants.
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Figure 2. Examples of genetic barrier for generating NS3/4A resistance mutations in HCV. The 
percentages given for each subtype (1a and 1b) have been calculated with the relevant triplets in a 
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Figure 2. Examples of genetic barrier for generating NS3/4A resistance mutations in HCV. The
percentages given for each subtype (1a and 1b) have been calculated with the relevant triplets in a
subtype alignment of sequences for GTs 1a and 1b HCV genomic sequences retrieved from [97] with
the condition of belonging to full genome sequences, and being devoid of large insertions/deletions
(M.E. Soria and C. Perales, unpublished results). The most represented triplets for GTs 1a and 1b
are boxed in red; “-“ in the place of a percentage means that the relevant triplet was not represented
among the compared sequences. “ts” and “tv” means transition and transversion, respectively. The
mutations needed at positions 36 and 155 (resistance to TPV and BOC, among others) are highlighted
in red. Data based on several publications quoted in the text.
The difference between resistance to IFN-α and resistance to an antiviral directed against a
specific viral target is interesting regarding the different demands on the quasi-species response.
Resistance to IFN-α must entail mutations to counteract multiple antiviral components whereas
resistance to a DAA is often associated with one or few amino acid replacements, generally in the
protein targeted by the inhibitor [98] (Section 4.2). When multiple mutations are needed to overcome
an antiviral response such as that induced by IFN-α, the amplitude of the mutant spectrum and the
capacity to explore sequence space becomes critical for virus escape (compare with Section 2). That
administration of IFN-α alone failed to clear HCV from many patients may be taken as an indication
of the multiple evolutionary resources that viral quasi-species exploit for survival [3].
An alternative is the use of designed drugs that target cellular functions required for the virus
to complete its infectious cycle, the so called host-targeted agents (HTAs). Since cellular targets
cannot vary in response to a viral infection they are an obvious choice to avoid selection of escape
mutants [99–103]. Pawlotsky listed 38 host factors involved in the HCV life cycle [104]. The HTAs
for HCV that have reached clinical assays or have been licensed for clinical use are inhibitors of
cyclophilin A [cyclosporin A (CsA), SCY-635, alisporivir or Debio 025, NIM 811], and miR-122
antagonists. However, two main problems are encountered with the use of HTAs: (i) side effects
due to alteration of cellular functions; and (ii) selection of viral escape mutants because the virus can
mutate to forms which are capable of by passing the HTA by several mechanisms ([105,106]; reviewed
in [3]). It is not clear which will be the contribution of HTAs to anti-HCV combinations displaying a
high barrier to resistance.
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4.3. HCV Inhibitor Resistance Independent of Specific Mutations
A study from our group showed that multiply passaged, high fitness HCV displayed increased
resistance to several anti-HCV inhibitors (TPV, DCV, RBV, CsA, and IFN-α) despite the different
mechanisms used to exert their antiviral activity. The resistance could not be associated with specific
mutations in any case. It was proposed that fitness or a fitness-related trait was responsible of
HCV resistance to multiple inhibitors [107]. The molecular basis and the possible clinical impact
are still under study but we proposed as a possible mechanism a competition between the number of
replicating genomes at each replicative unit in an infected cell and the concentration of inhibitor that
reaches the replicative units [107]. Experiments are in progress to explore this possibility. Regarding
the possible clinical significance of a fitness-dependent resistance in HCV, some patients do not
respond to treatment despite no evidence of resistance substitutions in the expected target protein
of the rebound HCV [90,108,109]; several mechanisms have been proposed to account for these
observations. If a fitness-related mechanism of HCV resistance operated in vivo, some treatment
failures would be expected independently of the epidemiological relevance that specific resistance
mutations attain in the human population. One of the problems is the difficulty of estimating HCV
fitness as the virus replicates in vivo. It cannot be excluded that mechanisms of drug resistance exist
that are dependent neither on specific mutations nor on a fitness-related trait. This is an important
question that has been raised with the new HCV treatments and that was not evident in the follow-up
of treatments of other viral diseases.
4.4. DAA Resistance Mutations in Naïve and Treatment-Experienced Patients: Effect of Natural and Selected
Resistance Mutations on Treatment Response
Two questions are open regarding the influence of resistance mutations in the efficacy of
HCV therapy. First, how naturally occurring resistance mutations in viral quasi-species from DAA
treatment-naïve patients can affect treatment resolution; and second, how resistance mutations that
have been selected as a consequence of a mutational pressure (previous failed treatments) will impact
future treatments with the same or a different antiviral drug [74].
With respect to the first question several studies have demonstrated that mutations conferring
resistance to NS3/4A, NS5A, or NS5B inhibitors can pre-exist in HCV-infected patients that have
not been previously treated with DAAs [110–115]. This is not surprising due to the high basal
mutation frequency in natural HCV populations. Currently, guidelines from the most important
medical associations (EASL and AASLD) only recommend the analysis of substitutions Q80K in
NS3/4A in naïve patients due to the high prevalence of this naturally-occurring variant for GT1a and
its clear association with decreased SVR after simeprevir-based triple therapy [116–118]. Increased
failure of the simeprevir-based triple therapy was observed after re-treatment of patients who had
developed simeprevir resistance during a previous monotherapy phase, which may be a consequence
of the persistence of resistance variants within the viral population [119]. We suspect that, as it
happened with antiretroviral therapies for HIV-1, analysis of multiple resistance mutations will be
recommended soon.
It is not clear which is the frequency of resistance mutations that can influence the treatment
success. It seems that the answer may depend on several variables, such as the viral GT, and
the antiviral combinations used. Regarding the effect of the viral GTs, a study using ultra deep
pyrosequencing (UDPS) during a long follow-up period in a cohort of patients treated with TPV
showed that TPV-resistant variants were amply present at baseline in more than 30% of the patients.
Although no general statistically significant differences in the preexistence of resistant mutants
between responders and non-responders have been consistently found, the detection of R155K/T/Q
at baseline predicted the failure for GT1a patients [115]. On the contrary, the analysis by UDPS
of NS3/4A and NS5B regions from 208 DAA-naïve patients infected with GT1a and 1b showed
that the prevalence of DAA-resistant mutants and the intrinsic genetic diversity was similar in both
isolates suggesting that the composition of the viral quasi-species might not be related to the lower
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virological response of GT1a as compared to GT1b [112]. Other studies have reported differences
in the prevalence of resistant mutants depending not only on the genotype but also on the HCV
target region. For instance, population sequencing at baseline in 406 GT1 patients revealed no
NS3/4A resistance mutations in GT1b whereas resistance mutations were present in 45% of the
GT1a sequences; the frequency of resistance substitutions in NS5A versus NS5B depended on the
viral subtype (15% and 25% for GT1a and 1b patients in NS5A, and 5% and 28% for GT1a and 1b
patients in NS5B) [120].
Regarding the second question or how previously selected resistance mutations can impact
future treatments, studies of mutant dynamics during quasi-species evolution in cell culture and
in vivo suggest that such previously selected mutations may be archived in the form of memory
genomes even in viruses that lack a DNA reservoir [121–123]. Memory is a consequence of
quasi-species behaving as complex adaptive systems, as follows. When a subpopulation of genomes
from a viral quasi-species is selected (for example by replicating in the presence of a drug), its
proportion in the population increases; because selection entails replication, its fitness increases.
When the selective pressure is removed (by eliminating the drug), the selected variants lose
dominance in the population. However, because the genomes gained fitness during the selective
step, their level in the mutant spectrum is higher than the original level (prior to selection) that was
dictated by mutational pressure and basal fitness (compare with the ranking of mutant spectrum
components according to fitness discussed in Section 3). When resistant mutants emerge and lead
to treatment failure in HCV-infected patients, it is not well known how long they may remain
in the population and impact future therapy. Some studies have revealed a loss of detection of
resistant variants [108,124], while in other studies, resistant variants were detected several years
after treatment with TPV or BOC [125], and after treatment with combinations including NS5A
inhibitors [126]. According to model studies in cell culture, the duration of memory genomes in
replicating viral populations depends on the fitness level they had when they were established as
memory genomes [127]. The data available do not permit anticipating how fitness levels might affect
maintenance of inhibitor resistance mutations in HCV from infected patients, although fitness effects
on the persistence of resistance mutations after treatment interruption are likely. It is also noteworthy
that some amino acid substitutions may impact resistance to several inhibitors (for example amino
acids 155, 156 and 168 of NS3/4A regarding resistance to protease inhibitors). Therefore, memory
can also impact the response to inhibitors other than the ones used in the first treatment. Memory has
also been documented with HIV-1 in vivo, and it may contribute to treatment failure when a patient is
treated for a second time with a drug that was already administered in a previous treatment [3,123].
5. Cell Culture Systems for the Study of Resistance Mutations
The understanding of fundamental processes in virology, including population dynamics, has
traditionally been based in combinations of observations in cell culture and in vivo. In the case of
HCV, having cell culture systems to examine virus replication has been particularly arduous. The
first HCV cell culture system that allowed an efficient HCV intracellular replication was achieved in
1999 by R. Bartenschlager’s laboratory [128]. Drug development against HCV, especially DAAs, has
been intimately linked to the improvements in the subgenomic replicon system. Despite a strictly
intracellular replication, these replicons contain the main targets for therapy (spanning the NS3/4A
protease to the NS5B polymerase coding regions), and open the way to the characterization of viral
resistance to DAAs [129,130]. As an example, the identification of BMS-790052 (former name of
DCV) was based on a high throughput drug screening using replicons [131]. The study of the
entire HCV life cycle was possible with the observation that the wild-type JFH1 genome of GT2a
produced infectious particles in cell culture [132–134]. Based on that, many cell culture systems
including JFH1-based chimeras have been developed. The first recombinant viruses were constructed
by replacing the core-NS2 region from the seven major GTs [135–141]. These constructions permitted
the analysis of the inhibitory activity of neutralizing antibodies and the screening of inhibitors
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targeting the core-NS2 [137,142,143]. One step forward in the development of GT-specific JFH1-based
chimeras has been the construction of HCV recombinants with sequences encoding the non-structural
proteins from NS3/4A to NS5A of different GTs [144–150]. These cell culture systems have opened
the possibility to study not only new aspects of the HCV biology (such as the determination of
genetic elements in the non-structural proteins that are similar or that vary among GTs), but also
the evaluation of the GT-specific efficacy of antiviral compounds directed against non-structural
proteins. These investigations are expected to be extended as the GT-specific cell culture systems
are improving, or cell cultures with increased HCV permissivity are developed [151].
The efficacy of NS3/4A protease inhibitors such as TPV, BOC, danoprevir, and vaniprevir was
evaluated in vitro using recombinant infectious cell culture systems expressing GT-specific NS3 (2a,
3a, 5a, and 6a). The efficacy of protease inhibitors was similar against GTs2a, 5a, and 6a and was
lower for GT3a [144]. NS5A is a main target of current DAAs and has been implicated in several
viral functions including replication and viral production. The identification of functional domains
within the NS5A protein that are important for all GTs might provide a means to develop antiviral
compounds active across the spectrum of GTs [146]. The sensitivity to DCV of NS5A-recombinant
viruses from GTs one to seven varied depending on the GT that provided the NS5A-coding
region, suggesting that GT and subtype are main determinants of the efficacy of specific inhibitors.
Conversely, the efficacy of IFN-α treatment was similar with all NS5A-chimeras tested, suggesting
that the complete NS5A gene is not sufficient to generate a GT-specific response to IFN-α in cell
culture [145]. This is consistent with the multigenic nature of IFN-α resistance in HCV, as emphasized
in Section 4.
To evaluate the GT-specific efficacy of combination treatments using NS3 and NS5A inhibitors in
the context of the complete viral life cycle, GT1a and 3a recombinants containing only NS3 helicase,
NS5B, and the 31 untranslated region from JFH1 were constructed. The concentrations of asunaprevir
(NS3 protease inhibitor) and DCV (NS5A inhibitor) needed to inhibit GT3a viruses were higher than
for GT1a. However, combination therapies of both compounds resulted in the suppression of viral
infectivity in all recombinants at relatively low concentrations [148].
The construction of molecular clones from GTs different from 2a that are able to produce
infectious viruses at high virus titers is one of the major challenges. The main interest for HCV
research is in GT1 since a large proportion of HCV infections worldwide are due to that GT. The
production of the GT1a infectious virus in cell culture has been improved from the Hutchinson
strain [152] to more highly efficient cell culture strains [153,154]; these systems represent a great tool
to assess resistance to protease inhibitors [155]. GT1b HCV strains that are able to produce infectious
particles have been also described [156,157].
The current view of HCV therapy that we have conveyed is not very distant from the conclusion
reached after 30 years of HIV-1 therapy. It will be extremely interesting to observe if new therapies
will allow the global eradication of HCV, a pathogen for which no silent DNA reservoirs are known.
6. Concluding Remarks and Perspectives
The introduction of DAAs in anti-HCV therapy offers hopes of unprecedented, elevated SVR
rates. Yet the problem of drug resistance and treatment failure continues being a limitation. The
history of waves of treatment options for HIV-1 infection revives for the hepatitis viruses, in particular
HCV. It should not be forgotten that there are still treatment protocols that await exploration. The
standard combination therapies may now be applied in modified ways that may further increase SVR
rates [158]. These new designs include two-phase split treatments, use of broad spectrum antiviral
agents based on stimulation of the innate immune response, or lethal mutagens—that achieve virus
extinction by an excess of deleterious mutations—introductions of drugs that target cellular functions
needed by the virus, or combinations of immunotherapy and pharmacology. In addition, when
a mutagenic agent participates in therapy (as is perhaps the case of RBV as part of its anti-HCV
activity) a sequential inhibitor-mutagen combination may have an advantage over the corresponding
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combination. These several possibilities have been opened as a result of theoretical and experimental
studies. It is beyond the scope of the present review article to cover them but the reader will find the
main points in some recent publication from our group [3,13,159].
These new possibilities respond to an increasing demand of new paradigms for the control
of infectious disease generally, and particularly the challenge of quasi-species swarms. Even if
SVRs for HCV treatment reached values close to 100% (a possibility still to be substantiated)
due to unprecedented economic investment, improved antiviral interventions will still be
needed for a number of emerging and reemerging diseases that are currently expanding as a
result of environmental changes, the perfect scenario for viral quasi-species to practice their
adaptive capabilities.
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